Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

書誌詳細
主要な著者:	Rea, D, Gray, R, Bowden, S, Handley, K, Earl, H, Poole, C, Bates, T, Dewar, J, Raytor, Z, Lee, M
フォーマット:	Conference item
出版事項:	2013

類似資料

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
著者:: Dennis C. Sgroi, 等
出版事項: (2022-12-01)

An Extraordinary New Toad (Bufo) ttom Costa Rica
著者:: Jay M Savage
出版事項: (2002-06-01)

Tamoxifen-independent recombination in the RIP-CreER mouse.
著者:: Yanmei Liu, 等
出版事項: (2010-10-01)

Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals
著者:: Joonatan Palmu, 等
出版事項: (2020-08-01)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
著者:: Qing Lv MD, PhD, 等
出版事項: (2021-03-01)

Testing the untestable in language education /
著者:: Paran, Amos, 等
出版事項: (c201)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
著者:: Liu Y, 等
出版事項: (2020-08-01)

CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.
著者:: Tian Gao, 等
出版事項: (2014-01-01)

Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model
著者:: Angel Pulido-Capiz, 等
出版事項: (2024-09-01)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
著者:: Yan Xiu Ouyang, 等
出版事項: (2021-06-01)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
著者:: Coralie Poulard, 等
出版事項: (2023-07-01)

A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia
著者:: Weili He, 等
出版事項: (2023-03-01)

USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα
著者:: Ting Zhuang, 等
出版事項: (2024-08-01)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
著者:: Angela Maselli, 等
出版事項: (2019-07-01)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging
著者:: Ying Li, 等
出版事項: (2020-04-01)

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.
著者:: Li Yin, 等
出版事項: (2014-01-01)

A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER− cells via endoplasmic reticulum stress-induced apoptosis
著者:: Tinglin Yang, 等
出版事項: (2024-02-01)

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
著者:: Lukasz Turczyk, 等
出版事項: (2017-10-01)

δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.
著者:: Shaocong Guo, 等
出版事項: (2012-01-01)

Five years of tamoxifen--or more?
著者:: Peto, R
出版事項: (1996)

Highlights of the first twenty years of the ERS, 1990-2010 past presidents of the ERS recall activities during their term of office
著者:: Donner Claudio F
出版事項: (2010-02-01)

ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
著者:: Sheng-Li Lin, 等
出版事項: (2010-02-01)

Video er TV er video
著者:: Susanna Neimann
出版事項: (1988-08-01)

Video er TV er video
著者:: Susanna Neimann
出版事項: (1988-08-01)

ERβ Isoforms Have Differential Clinical Significance in Breast Cancer Subtypes and Subgroups
著者:: Young Choi, 等
出版事項: (2022-04-01)

NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
著者:: Yu Cheon Kim, 等
出版事項: (2021-06-01)

circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells
著者:: Zheng Li, 等
出版事項: (2023-07-01)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models.
著者:: Wei Zou, 等
出版事項: (2015-01-01)

Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer
著者:: Sarra M. Rahem, 等
出版事項: (2020-11-01)

Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription Profiling
著者:: Chindo Hicks, 等
出版事項: (2012-02-01)

Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer
著者:: Runyi Ye, 等
出版事項: (2021-09-01)

Untested natural medicines are big threats to health in China and Africa
著者:: Minghui Zhang
出版事項: (2020-07-01)

Peculiarities of gastroduodenal pathology in children in the families of parents with untested dyspepsia
著者:: V. V. Tsukanov, 等
出版事項: (2019-07-01)

Diallel analysis and prediction of untested maize single cross hybrids
著者:: José Lidércio Matias Júnior, 等
出版事項: (2019-02-01)

Diallel analysis and prediction of untested maize single cross hybrids
著者:: José Lidércio Matias Júnior, 等
出版事項: (2019-02-01)

ASCLD statement on volume of untested sexual assault evidence kits
著者:: Laura Sudkamp, 等
出版事項: (2020-01-01)

Importance of untested infectious individuals for interventions to suppress COVID-19
著者:: Francisco J. Pérez-Reche, 等
出版事項: (2021-10-01)

WHO-ERS train the trainer in smoking cessation: Three years' experience
著者:: Paraskevi Katsaounou
出版事項: (2019-10-01)

Det er dansk - eller er det?
著者:: Søren Schou
出版事項: (1987-08-01)

Det er dansk - eller er det?
著者:: Søren Schou
出版事項: (1987-08-01)